Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...
Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
While Eli Lilly and Company (NYSE:LLY) generated $1.2 billion in sales from Zepbound in the second quarter, it is also ...
1don MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback